Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project

被引:37
作者
Eastell, Richard [1 ]
Vittinghoff, Eric [2 ]
Lui, Li-Yung [3 ]
McCulloch, Charles E. [2 ]
Pavo, Imre [4 ]
Chines, Arkadi [5 ]
Khosla, Sundeep [6 ]
Cauley, Jane A. [7 ]
Mitlak, Bruce [8 ]
Bauer, Douglas C. [2 ]
Bouxsein, Mary [9 ,10 ]
Black, Dennis M. [2 ]
机构
[1] Univ Sheffield, Acad Unit Bone Metab, Sheffield, S Yorkshire, England
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA
[3] Calif Pacific Med Ctr, San Francisco, CA USA
[4] Eli Lilly & Co, Lilly Res Ctr, Windlesham, Surrey, England
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Mayo Clin, Coll Med, Rochester, MN USA
[7] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA
[8] Radius Hlth, Boston, MA USA
[9] Beth Israel Deaconess Med Ctr, Ctr Adv Orthoped Studies, Dept Orthoped Surg, Boston, MA 02215 USA
[10] Harvard Med Sch, Boston, MA 02115 USA
基金
英国医学研究理事会;
关键词
BONE MINERAL DENSITY; FRACTURE; SURROGATE; BISPHOSPHONATES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; INTRAVENOUS IBANDRONATE INJECTIONS; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURE; SODIUM-FLUORIDE; RANDOMIZED-TRIAL; ZOLEDRONIC ACID; META-REGRESSION; DOUBLE-BLIND; OSTEOPOROSIS; RISK;
D O I
10.1002/jbmr.4433
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The surrogate threshold effect (STE) is defined as the minimum treatment effect on a surrogate that is reliably predictive of a treatment effect on the clinical outcome. It provides a framework for implementing a clinical trial with a surrogate endpoint. The aim of this study was to update our previous analysis by validating the STE for change in total hip (TH) BMD as a surrogate for fracture risk reduction; the novelty of this study was this validation. To do so, we used individual patient data from 61,415 participants in 16 RCTs that evaluated bisphosphonates (nine trials), selective estrogen receptor modulators (four trials), denosumab (one trial), odanacatib (one trial), and teriparatide (one trial) to estimate trial-specific treatment effects on TH BMD and all, vertebral, hip, and nonvertebral fractures. We then conducted a random effects meta-regression of the log relative fracture risk reduction against 24-month change in TH BMD, and computed the STE as the intersection of the upper 95% prediction limit of this regression with the line of no fracture reduction. We validated the STE by checking whether the number of fractures in each trial provided 80% power and determining what proportion of trials with BMD changes >= STE reported significant reductions in fracture risk. We applied this analysis to (i) the trials on which we estimated the STE; and (ii) trials on which we did not estimate the STE. We found that the STEs for all, vertebral, hip, and nonvertebral fractures were 1.83%, 1.42%, 3.18%, and 2.13%, respectively. Among trials used to estimate STE, 27 of 28 were adequately powered, showed BMD effects exceeding the STE, and showed significant reductions in fracture risk. Among the validation set of 11 trials, 10 met these criteria. Thus STE differs by fracture type and has been validated in trials not used to develop the approach. (c) 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
引用
收藏
页码:29 / 35
页数:7
相关论文
共 41 条
[1]   Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization [J].
Amur, S. ;
LaVange, L. ;
Zineh, I. ;
Buckman-Garner, S. ;
Woodcock, J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) :34-46
[2]   Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].
Black, Dennis M. ;
Delmas, Pierre D. ;
Eastell, Richard ;
Reid, Ian R. ;
Boonen, Steven ;
Cauley, Jane A. ;
Cosman, Felicia ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Mautalen, Carlos ;
Mesenbrink, Peter ;
Hu, Huilin ;
Caminis, John ;
Tong, Karen ;
Rosario-Jansen, Theresa ;
Krasnow, Joel ;
Hue, Trisha F. ;
Sellmeyer, Deborah ;
Eriksen, Erik Fink ;
Cummings, Steven R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822
[3]  
Black DM, 2020, LANCET DIABETES ENDO, V8, P672, DOI 10.1016/S2213-8587(20)30159-5
[4]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[5]   Long-term effect of strontium ranelate treatment on BMD [J].
Blake, GM ;
Fogelman, G .
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (11) :1901-1904
[6]   Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials [J].
Bouxsein, Mary L. ;
Eastell, Richard ;
Lui, Li-Yung ;
Wu, Lucy A. ;
de Papp, Anne E. ;
Grauer, Andreas ;
Marin, Fernando ;
Cauley, Jane A. ;
Bauer, Douglas C. ;
Black, Dennis M. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (04) :632-642
[7]   A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [J].
Chesnut, CH ;
Silverman, S ;
Andriano, K ;
Genant, H ;
Gimona, A ;
Harris, S ;
Kiel, D ;
LeBoff, M ;
Maricic, M ;
Miller, P ;
Moniz, C ;
Peacock, M ;
Richardson, P ;
Watts, N ;
Baylink, D .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (04) :267-276
[8]   Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis [J].
Chesnut, CH ;
Skag, A ;
Christiansen, C ;
Recker, R ;
Stakkestad, JA ;
Hoiseth, A ;
Felsenberg, D ;
Huss, H ;
Gilbride, J ;
Schimmer, RC ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1241-1249
[9]   Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward [J].
Ciani, Oriana ;
Buyse, Marc ;
Drummond, Michael ;
Rasi, Guido ;
Saad, Everardo D. ;
Taylor, Rod S. .
VALUE IN HEALTH, 2017, 20 (03) :487-495
[10]   Romosozumab Treatment in Postmenopausal Women with Osteoporosis [J].
Cosman, F. ;
Crittenden, D. B. ;
Adachi, J. D. ;
Binkley, N. ;
Czerwinski, E. ;
Ferrari, S. ;
Hofbauer, L. C. ;
Lau, E. ;
Lewiecki, E. M. ;
Miyauchi, A. ;
Zerbini, C. A. F. ;
Milmont, C. E. ;
Chen, L. ;
Maddox, J. ;
Meisner, P. D. ;
Libanati, C. ;
Grauer, A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (16) :1532-1543